Biomarker-Driven Lung Cancer

Lorlatinib has been granted a breakthrough therapy designation by the FDA for use in patients with <em>ALK</em>-positive metastatic non-small cell lung cancer who have previously received 1 or more ALK inhibitors.

Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M&nbsp;</em>mutation-positive non&ndash;small cell lung cancer, regardless of prior treatment with an EGFR TKI.

Matthew Gubens, MD, sheds light on how far the field has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Immunotherapy has made a significant impact in the field of non&ndash;small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.

Veliparib fell short of meeting the primary endpoint&nbsp;in a phase III non&ndash;small cell lung cancer trial and a triple-negative breast cancer trial.

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer

Nuances in Treating Squamous Cell Lung Cancer

Leena Gandhi, MD, PhD, discusses&nbsp;the ongoing phase III ALEX study, which is exploring alectinib as a first-line treatment option for&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer.

Julie R. Brahmer, MD, discusses&nbsp;5-year follow-up data from the CA209-003 study of nivolumab for patients with metastatic non&ndash;small cell lung cancer.

Sukhmani Padda, MD, discusses&nbsp;the status of ongoing trials participating in the race to the frontline in lung cancer.

According to findings from the phase III ALEX trial, alectinib reduced the risk of disease progression or death compared with crizotinib as a frontline treatment for patients with <em>ALK</em>-positive non&ndash;small cell lung cancer.&nbsp;

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.